CTLA4 and cervical cancer: In a phase I/II trial investigating the effects of ipilimumab (anti-CTLA-4) monotherapy in patients with metastatic or recurrent cervical cancer (n = 42), there was an overall response rate of only 2.9% (1/42; 1 PR) [182].